Dendritic cells are poised to revolutionize oncology. This type of immune therapy shows effectiveness even in late-stage ...

The new machinery, called a "chimeric antigen receptor" or "Car," transforms a diverse T-cell population into Car-T, where the engineered cells all respond to the same cancer-associated marker. Both ...

The heart tissue showed upregulation of molecular pathways that help recruit and retain immune cells involved in inflammation ...

The phase 2 CELLVX-230 trial is assessing the potential of FK-PC101 to prevent prostate cancer recurrence and delay ...

Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral ImmunotherapyCompany founded by 4BIO Capital and ...

A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising ...

Trials with mice in whom the researchers implanted human glioblastoma cells have already shown that the treatment is very ...

Researchers develop a plug-and-play test that enables real-time monitoring of engineered T-cells, improving the precision and ...

AC Immune reports interim results from Phase 2 trial of ACI-7104.056 active immunotherapy for early Parkinson's disease.

T cell-based immunotherapies including immune checkpoint blockade and chimeric antigen receptor T cells can induce durable responses in patients with cancer. However, clinical efficacy is limited due ...

A2 Bio shares clinical study progress and the increased diversity of participants in the BASECAMP-1 prescreening study during the SITC annual meeting.

Some patients being treated with immune checkpoint inhibitors, a type of cancer immunotherapy, develop a dangerous form of heart inflammation called myocarditis. Researchers have now uncovered the ...